Fenwick represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced the...
You must be a Standard 1 Year member to access this content.
Fenwick represented Versa Networks on the deal. Versa Networks, a recognized leader of single-vendor Secure Access Service Edge (SASE) platforms, announced its $120 million financing. The round...
You must be a Standard 1 Year member to access this content.
Fenwick represented Collide Capital on the deal. Collide Capital, one of the largest Black-owned first-time funds, announced the launch of its $66 million inaugural fund. Collide Capital...
You must be a Standard 1 Year member to access this content.
Fenwick represented UserTesting, Kirkland & Ellis represented Thoma Bravo, Goodwin Procter advised Sunstone Partners on the deal. UserTesting, a video-based human insight company, announced its acquisition by...
You must be a Standard 1 Year member to access this content.
Fenwick represented Landis on the deal. Landis, a financial education and coaching platform making the path to homeownership more accessible, announced its $40 million Series B financing....
You must be a Standard 1 Year member to access this content.
Covington advised Insmed Incorporated on the deal while Fenwick represented Pharmakon. Walder Wyss advised the funds managed by Pharmakon Advisors, LP, BioPharma Credit and OrbiMed. Akin...
You must be a Standard 1 Year member to access this content.
Fenwick represents Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced IP diligence...
You must be a Standard 1 Year member to access this content.
Fenwick represented Folx Health on the deal. Folx Health, a digital healthcare service provider designed by and for the medical needs of the LGBTQIA+ community, announced its...
You must be a Standard 1 Year member to access this content.
Fenwick represented TripActions on the deal. TripActions, a travel and spend management platform, announced its $154 million Series G at a valuation to $9.2 billion, including new...
You must be a Standard 1 Year member to access this content.
Fenwick represented Knock on the deal. Knock, a provider of customer relationship management (CRM) and front office technology in the multifamily industry, announced its acquisition by RealPage,...
You must be a Standard 1 Year member to access this content.
Fenwick represented SyntheX on the deal. SyntheX, a biotechnology company innovating next-generation functional drug discovery engines, announced its research collaboration and license agreement with Bristol Myers...
You must be a Standard 1 Year member to access this content.
Fenwick represented Aceragen on the deal, Morgan Lewis advised Idera Pharmaceuticals. Aceragen, a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there...
You must be a Standard 1 Year member to access this content.
